Comparison · NCT01006252-sae
Tasisulam-sodium vs Paclitaxel: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Tasisulam-sodium vs Paclitaxel: serious adverse events. Trial comparisons, record NCT01006252-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01006252-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.323 | 0.256 | 0.398 | wilson | |
| Risk in group 2 | 0.273 | 0.21 | 0.347 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0499 | -0.0495 | 0.148 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.18 | 0.846 | 1.65 | log | |
| Odds ratio, group 1 over group 2 | 1.27 | 0.788 | 2.05 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Tasisulam-sodium than on Paclitaxel | 20 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Tasisulam-sodium | Individualized tasisulam-sodium dose was dependent on participant's height, weight, and gender. Dose was adjusted based on laboratory parameters. Treatment was administered intravenously on Day 1 of a 28-day cycle, until disease progression. | 53 | 164 | EG000 |
| Group 2 | Paclitaxel | Paclitaxel 80 mg/m\^2 administered intravenously on Days 1, 8, and 15 of a 28-day cycle, until disease progression | 44 | 161 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma
- NCT number
- NCT01006252
- Phases
- PHASE3
- Conditions
- Melanoma
- Interventions
- Tasisulam-sodium, Paclitaxel
- Lead sponsor
- Eli Lilly and Company
- Results first posted
- 2018-07-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01006252?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01006252-sae